The Study of Pharmacokinetics Parameters of Morphine Hydrochloride, Long-acting Tablets in Cancer Patients with Severe Chronic Pain Syndrome

Introduction. Effective drug therapy for cancer patients with chronic pain syndrome (CPS) of high intensity is one of the priorities of modern healthcare. Currently, non-narcotic and narcotic analgesics are used for pain relief according to a three-steps scheme. In the absence of contraindications, it is preferable to prescribe medications per os and prolonged forms, which will allow the patient to maintain selfcare and comfort.

Aim. To study the pharmacokinetic properties of a drug with a prolonged mechanism of action «Morphine hydrochloride», in a film-coated tablet formof a dosage 30 mg, in cancer patients with severe CPS.

Materials and methods. For the analysis of the pharmacokinetics of the studied drug after single and multiple doses of 20 patients who received 10-day analgesic therapy with the studied drug «Morphine hydrochloride», long-acting film-coated 30 mgtablets. manufacturer FSUE Moscow Endocrine Plant, Russia. Route of administration: per os. The study duration was 17 days: screening duration up to 7 days; duration of therapy up to 10 days.

Results and discussion. The concentration of morphine in plasma was determined by HPLC-tandem mass spectrometry, within 12 hours after taking the study drug (1 of long-acting, film-coated tablet 30 mg). The following pharmacokinetic parameters were obtained on Day 5: T_1/2 – 6.08 ± 4.37 hours and 14.46 ± 30.86 hours, T_max – 2.5 ± 1.86 hours, C_max – 43.91 ± 27.24 ng/ml. Values of pharmacokinetic parameters averaged over all days are presented. It was found that T_1/2 for the studied drug T_1/2 is 9.21 ± 14.94 hours, T_max 2.87 ± 2.36 hours. The average maximum concentration (C_max) on the day of the study drug was 36.52 ng/ml.

Conclusion. As a result of the study of pharmacokinetics, it was found that the drug «Morphine hydrochloride», long-acting tablets film-coated with a of 30 mg was found in serum after oral administration after 15 minutes and reaches a maximum concentration in the blood in 3 hours, the half-life is on average 9 hours, the maximum concentration is 36.52 ng/ml.

1. Order of the Ministry of Health of the Russian Federation dated April 14, 2015 No. 187n «On approval of the Procedure for the provision of palliative care for adults» Recommendations of the European Association of Palliative Care: «White Paper: standards and norms of hospice and palliative care» (in Russ.).

2. Abuzarova G. R., Alekseeva G. S., Nigmatullina Z. Sh., Kuznetsov S. V. Availability of narcotic analgesics for the treatment of pain in Oncology. Russian journal of pain. 2013; 3: 48–54 (in Russ.).

3. Federal law 361-FZ «On circulation of medicines» of 12.04.2010 [Order of the government of the Russian Federation of 01.07.2016 n 1403-R «on approval of the action plan («road map») «increasing the availability of narcotic drugs and psychotropic substances for medical use»] (in Russ.).

4. Nevzorova D. V., Abuzarova G. R. Clinical guidelines: chronic pain syndrome in adult patients requiring palliative care. Therapy. 2017; 32: 69–75. (in Russ.).

5. Аbuzarova G. R., Alekseeva G. S., Sarmanaeva R. R., Dushakova L. V. Modern possibilities of import substitution in the treatment of pain syndrome in cancer patients. Research’n Practical Medicine Journal. 2014; 1(1): 8–15. (in Russ.).

6. Palekhov A. V., Vvedenskaya E. S. Opioid analgesics in the therapy of chronic pain: Problems and Promises. Russian Journal of Pain. 2015; 40(3): 56–63 (in Russ.).

7. Berezikova O., Usenko O., Berezikov V., Sharafutdinov M. Access to Opioids in Two Regions of Russia. Palliat. Med. 2012; 26(4): 458.6.

8. Dowell D., Haegerich T. M., Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain United States. JAMA. 2016; 315(15): 1624–1645. Doi: 10.1001/jama.2016.1464.

9. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012; 72(2): 181–90. Doi: 10.2165/11597260-000000000-00000.8.

10. Lebedeva M. V., Kononova S. V. Pharmacoeconomical explanation for choosing a prolonged formulation of morphine to reducechronic pain syndrome in oncologic patients. Bashkortostan Medical Journal. 2016; 11(3(63)): 58–61 (in Russ.).

11. Liao Q., Deng Y., Xie Z., Pan B., Zhang L. Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/ MS: application to a clinical pharmacokinetic study. J Sep Sci. 2009; 32(2): 202–211.

12. Ghassabian S., Moosavi S. M., Valero Y. G., Shekar K., Fraser J. F., Smith M. T. High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 903: 126–133.

13. Baillie S. P., Bateman D. N., Coates P. E., Woodhouse K. W. Age and the Pharmacokinetics of Morphine. Age and Ageing. 1989; 18(4): 258–262. Doi: 10.1093/ageing/18.4.258.

14. Drake J., Kirkpatrick C. T., Aliyar C. A., Crawford F. E., Gibson P., Horth C. E. Boehringer Ingelheim Ltd, Bracknell. Charterhouse Clinical Research Unit, The Royal Masonic Hospital, London, 3Ethical Pharmaceuticals Ltd, Ely, Bioanalytical Research Ltd, Ely and 5Biomedical Consultant, Cytops, High Wycombe, UK.